FDA Clears IND for Oral Epetraborole Phase 2 in Polycythemia Vera; Trial Starts Q4
ANTX has more than doubled off its 52-week low of $1.
Summary
AN2 got FDA IND clearance for epetraborole in polycythemia vera, completing the regulatory package alongside Australia and India authorizations. The company plans to start the global Phase 2 trial in Q4 2026, an open-label sentinel and dose-optimization phase followed by a randomized, placebo-controlled cohort in phlebotomy-dependent PV patients. This is the third Phase 2 program the company expects active in 2026, per its Q2 disclosure of $79.9M in cash with runway into 2029. For a micro-cap clinical-stage name, moving a pipeline asset into the clinic is the main value driver, though the readout is years away and the $80M ATM remains an overhang. Watch for trial initiation in Q4 2026.
At the time of this announcement, ANTX was trading at $4.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $170.9M. The 52-week trading range was $1.00 to $7.19. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.